id: sud_treatment_facility_density_to_substance_use_disorder_any
name: SUD Treatment Facility Density â†’ Substance Use Disorder (Any)
from_node:
  node_id: sud_treatment_facility_density
  node_name: SUD Treatment Facility Density
to_node:
  node_id: substance_use_disorder_any
  node_name: Substance Use Disorder (Any)
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Limited treatment options for SUDs create barriers to care access'
- 'Step 2: Novel treatments like ketamine may expand therapeutic options where approved'
- 'Step 3: Increased treatment availability improves access for patients with SUDs'
- 'Step 4: Greater treatment access reduces unmet need and improves outcomes across substance types'
evidence:
  quality_rating: B
  n_studies: 14
  primary_citation: 'Reinhard Janssen-Aguilar et al. 2025. "Role of ketamine in the treatment of substance
    use disorders: A systematic review.." https://doi.org/10.1016/j.josat.2025.209705'
  supporting_citations:
  - Systematic review of 14 studies with 551 participants across multiple SUDs
  - Studies examined alcohol, cocaine, opioid, and cannabis use disorders
  - Evidence supports short-term benefits of ketamine for SUD treatment
  doi: 10.1016/j.josat.2025.209705
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: This systematic review highlights the limited treatment options for substance use disorders
  and the potential role of ketamine as a novel therapeutic option. Despite global prevalence and burden
  of SUDs, treatment options remain limited, creating structural barriers to recovery.
quantitative_effects:
  sample_size: 551
moderators:
- name: treatment_modality
  direction: strengthens
  strength: moderate
  description: Combination of ketamine with psychotherapy (50% of studies) may enhance treatment effects
    compared to pharmacological treatment alone
- name: study_duration
  direction: strengthens
  strength: weak
  description: Study endpoints ranged from less than a day to two years; longer-term outcomes require
    further research
structural_competency:
  equity_implications: The paper explicitly notes that 'treatment options remain limited' for SUDs despite
    their global prevalence and burden. This represents a structural failure in healthcare systems to
    adequately address addiction. Ketamine's potential as a treatment option must be evaluated in the
    context of healthcare access disparities, cost barriers, and the need for well-controlled research
    before broader implementation. The paper appropriately calls for larger studies and assessment of
    risks including abuse liability.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.952873'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
